•  
  •  
  •  
  •  

2026-02-08 05:32:38

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Fusion Finance Q3 FY26: Disbursements Surge 23% QoQ to ₹1,594 Cr, PAT Swings to ₹14 Cr Profit
  • Nifty Recovers 200 Points to End the Session Near Day high
  • Gateway Distriparks Q3 FY26: Revenue Soars 39% to ₹566 Cr, PAT Up 4% - Declares ₹2 Special Dividend on Debt-Free Milestone
  • Mamaearth Onboards Sreeleela as Hair Care Category Brand Ambassador; Unveils Valentine's Day Film for Rosemary Anti-Hair Fall Shampoo
  • Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%

Keywords Selected:  Injection

Stock Report

  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
  • Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Lupin Launches Liraglutide Injection in the United States
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer
  • Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
  • Gland Pharma receives approval from USFDA for Cangrelor for Injection 50 mg/vial
  • Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Gland Pharma Receives Approval for Angiotensin II Acetate Injection
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Haloperidol Decanoate Injection
  • Gland Pharma receives approval for Acetaminophen Injection
  • Amneal Pharmaceuticals launches 2nd NDA Bortezomib for injection3.5mg/1.4ml in US
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Pantoprazole Sodium for Injection, 40 mg/vial - Single-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
  • Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial

Latest Post

  • Fusion Finance Q3 FY26: Disbursements Surge 23% QoQ to ₹1,594 Cr, PAT Swings to ₹14 Cr Profit
  • Nifty Recovers 200 Points to End the Session Near Day high
  • Gateway Distriparks Q3 FY26: Revenue Soars 39% to ₹566 Cr, PAT Up 4% - Declares ₹2 Special Dividend on Debt-Free Milestone
  • Mamaearth Onboards Sreeleela as Hair Care Category Brand Ambassador; Unveils Valentine's Day Film for Rosemary Anti-Hair Fall Shampoo
  • Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025